- Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
- Exact Sciences Earns 2024 Great Place To Work® Certification™
- Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
- Exact Sciences Announces First-Quarter 2024 Results
- Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
- Exact Sciences to Participate in May Investor Conference
- Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
- Exact Sciences Schedules First Quarter 2024 Earnings Call
- Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
- Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 51.00 |
---|---|
High | 54.00 |
Low | 50.53 |
Bid | 51.84 |
Offer | 51.93 |
Previous close | 54.08 |
Average volume | 3.56m |
---|---|
Shares outstanding | 184.53m |
Free float | 182.72m |
P/E (TTM) | -- |
Market cap | 9.98bn USD |
EPS (TTM) | -1.32 USD |
Data delayed at least 15 minutes, as of May 24 2024 18:01 BST.
More ▼